

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




9903581-8
IP05'

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 295/06, A61K 31/495, C07D 405/10		A1	(11) International Publication Number: WO 98/33784
			(43) International Publication Date: 6 August 1998 (06.08.98)
(21) International Application Number: PCT/US98/01628 (22) International Filing Date: 29 January 1998 (29.01.98) (30) Priority Data: 08/791,673 30 January 1997 (30.01.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/791,673 (CON) Filed on 30 January 1997 (30.01.97) (71) Applicant (for all designated States except US): NEUROGEN CORPORATION [US/US]; 35 N.E. Industrial Boulevard, Branford, CT 06405 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): THURKAUF, Andrew [US/US]; 16 Fox Den Road, Danbury, CT 06811 (US). CHEN, Xi [US/US]; 144 East Main Street, Clinton, CT 06413 (US). (74) Agent: SARUSSI, Steven, J.; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4)



(1)

(57) Abstract

Disclosed are compounds of formula (I) or the pharmaceutically acceptable addition salts thereof wherein: R₁ is halogen or C₁-C₄ alkyl; and R₂ and R₃ are the same or different and represent hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, alkylthio, hydroxy, amino, mono(C₁-C₄)alkylamino, di(C₁-C₄)alkylamino, or R₂ and R₃ together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are dopamine D₄(ant)agonists and useful in the treatment of neuropsychological diseases such as schizophrenia, psychotic depression and mania.